FILE:LIFE/LIFE-8K-20110511165238.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
Table of Contents
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
 
 
Table of Contents
Item 8.01  Other Events
     On May 11, 2011, Life Technologies Corporation (the "Company") sent notice to holders of the Company's 3.25% Convertible Senior Notes, Due 2025 (the "Notes") that the Company will optionally redeem all of the outstanding Notes on June 15, 2011 pursuant to Section 3.1 of the Indenture, dated June 20, 2005 between Life Technologies Corporation (formerly known as Invitrogen Corporation) and U.S. Bank National Association. Holders of the Notes have until 5:00 p.m. Eastern Time on June 14, 2011 to convert their Notes into shares of the Company's Common Stock and cash in accordance with the Indenture.
     U.S. Bank National Association is the trustee (the "Trustee") for the holders of the Notes under the Indenture. All questions relating to the mechanics of the redemption or conversion of the Notes should be directed to Paula Oswald at U.S. Bank National Association, telephone number (213) 615-6043.
     This announcement is only a summary of certain provisions of the Notes and the Indenture. A complete explanation of the conversion rights of holders of the Notes, as well as the procedures required to convert the Notes, is set forth in the Indenture. All holders are urged to review the conversion provisions contained in the Notes and the Indenture in their entirety.
     On May 11, 2011, the Company issued a press release regarding the redemption of the Notes. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01  Financial Statements and Exhibits.
     (d) Exhibits.
     99.1     Life Technologies Corporation press release dated May 11, 2011.
Table of Contents
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 11, 2011

Exhibit 99.1
Life Technologies Corporation (NASDAQ: LIFE) announced today that it has given notice of its intention to redeem all of the outstanding 3.25% Convertible Senior Notes due 2025 (the "2025 Convertible Notes") on June 15, 2011. As of May 6, 2011 there was $350,000,000 in aggregate principal amount of the 2025 Convertible Notes outstanding. The redemption notice provided includes CUSIP Numbers: 46185RAL4 and 46185RAM2.
CARLSBAD, Calif., May 11, 2011 (PR Newswire) 
The 2025 Convertible Notes are convertible at any time prior to 5:00 p.m. Eastern Time, June 14, 2011 at a rate of 20.3560 shares of common stock per $1,000 principal amount of the 2025 Convertible Notes surrendered. The 2025 Convertible Notes surrendered for conversion will be settled in cash and stock in accordance with the provisions of the indenture.
The U.S. Bank National Association, the trustee for the 2025 Convertible Notes, is mailing a Notice of Redemption to all registered holders of the 2025 Convertible Notes on May 11, 2011. Copies of such Notice of Redemption and additional information relating to the procedure for redemption and/or conversion of the 2025 Convertible Notes may be obtained from the U.S. Bank National Association by calling (800) 934-6802.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: .
http://www.lifetechnologies.com
Contact Information:
Eileen Pattinson 760-603-7208 ir@lifetech.com Agnes Lee 760-268-7971 agnes.lee@lifetech.com


